25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALXO (Alx Oncology HoldingsĀ ) Stock Analysis
Buy, Hold or Sell?

Let's analyze Alx Oncology HoldingsĀ  together

I guess you are interested in Alx Oncology HoldingsĀ . Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • šŸ“Š Fundamental Analysis (FA) – Alx Oncology Holdings ’s Financial Insights
  • šŸ“ˆ Technical Analysis (TA) – Alx Oncology Holdings ’s Price Targets

I'm going to help you getting a better view of Alx Oncology HoldingsĀ . At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Alx Oncology HoldingsĀ 

I send you an email if I find something interesting about Alx Oncology HoldingsĀ .

1. Quick Overview

1.1. Quick analysis of Alx Oncology HoldingsĀ  (30 sec.)










1.2. What can you expect buying and holding a share of Alx Oncology HoldingsĀ ? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
8.0%

What is your share worth?

Current worth
$1.65
Expected worth in 1 year
$0.23
How sure are you?
16.0%

+ What do you gain per year?

Total Gains per Share
$-1.42
Return On Investment
-262.7%

For what price can you sell your share?

Current Price per Share
$0.54
Expected price per share
$0.4051 - $1.19
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Alx Oncology HoldingsĀ  (5 min.)




Live pricePrice per Share (EOD)
$0.54
Intrinsic Value Per Share
$-19.35 - $-22.36
Total Value Per Share
$-17.70 - $-20.71

2.2. Growth of Alx Oncology HoldingsĀ  (5 min.)




Is Alx Oncology HoldingsĀ  growing?

Current yearPrevious yearGrowGrow %
How rich?$88.2m$183.8m-$59.3m-47.6%

How much money is Alx Oncology HoldingsĀ  making?

Current yearPrevious yearGrowGrow %
Making money-$32.5m-$41.5m$9m27.8%
Net Profit Margin0.0%-458.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Alx Oncology HoldingsĀ  (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#358 / 874

Most Revenue
#840 / 874

Most Profit
#706 / 874

Most Efficient
#202 / 874
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Alx Oncology HoldingsĀ ?

Welcome investor! Alx Oncology HoldingsĀ 's management wants to use your money to grow the business. In return you get a share of Alx Oncology HoldingsĀ .

First you should know what it really means to hold a share of Alx Oncology HoldingsĀ . And how you can make/lose money.

Speculation

The Price per Share of Alx Oncology HoldingsĀ  is $0.5407. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alx Oncology HoldingsĀ .
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alx Oncology HoldingsĀ , you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.65. Based on the TTM, the Book Value Change Per Share is $-0.36 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alx Oncology HoldingsĀ .

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.58-106.4%-0.61-112.5%-0.78-143.8%-0.66-122.7%-0.54-99.8%-0.45-84.0%
Usd Book Value Change Per Share-0.47-87.6%-0.36-65.7%-0.36-65.9%-0.40-73.6%-0.01-1.9%0.0712.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.47-87.6%-0.36-65.7%-0.36-65.9%-0.40-73.6%-0.01-1.9%0.0712.2%
Usd Price Per Share0.62-2.54-9.59-6.83-22.33-17.86-
Price to Earnings Ratio-0.27--0.97--3.19--2.54--15.62--12.50-
Price-to-Total Gains Ratio-1.31--18.89--1.43--12.55--34.81--34.81-
Price to Book Ratio0.38-0.97-2.81-1.80-3.11-2.49-
Price-to-Total Gains Ratio-1.31--18.89--1.43--12.55--34.81--34.81-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.5407
Number of shares1849
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.36-0.01
Usd Total Gains Per Share-0.36-0.01
Gains per Quarter (1849 shares)-656.48-18.66
Gains per Year (1849 shares)-2,625.91-74.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-2626-26360-75-85
20-5252-52620-150-160
30-7878-78881-225-235
40-10504-105141-300-310
50-13130-131401-374-385
60-15755-157661-449-460
70-18381-183922-524-535
80-21007-210182-599-610
90-23633-236442-674-685
100-26259-262702-749-760

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.025.00.00.0%0.025.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.018.03.016.0%4.018.03.016.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%2.00.018.010.0%2.00.023.08.0%2.00.023.08.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.018.03.016.0%4.018.03.016.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Alx Oncology HoldingsĀ  compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.474-0.355-25%-0.356-25%-0.398-16%-0.010-98%0.066-817%
Book Value Per Share--1.6522.330-29%3.440-52%3.649-55%4.302-62%3.516-53%
Current Ratio--5.4715.4850%7.152-24%7.957-31%17.561-69%15.204-64%
Debt To Asset Ratio--0.2700.255+6%0.204+32%0.191+41%0.183+47%0.191+41%
Debt To Equity Ratio--0.3690.344+7%0.182+102%0.205+80%0.191+93%0.157+135%
Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Enterprise Value--98521612.000225499123.000-56%653284850.000-85%522563557.667-81%1464576606.947-93%1464576606.947-93%
Eps---0.575-0.608+6%-0.777+35%-0.663+15%-0.540-6%-0.454-21%
Ev To Ebitda Ratio---0.774-1.687+118%-4.140+435%-3.710+379%-19.015+2356%-19.015+2356%
Free Cash Flow Per Share---0.463-0.510+10%-0.661+43%-0.543+17%-0.441-5%-0.371-20%
Free Cash Flow To Equity Per Share---0.461-0.380-18%-0.368-20%-0.387-16%-0.011-98%0.064-822%
Gross Profit Margin--1.0001.0010%1.0030%1.0010%1.0010%1.0010%
Intrinsic Value_10Y_max---22.360----------
Intrinsic Value_10Y_min---19.350----------
Intrinsic Value_1Y_max---2.184----------
Intrinsic Value_1Y_min---2.145----------
Intrinsic Value_3Y_max---6.606----------
Intrinsic Value_3Y_min---6.306----------
Intrinsic Value_5Y_max---11.079----------
Intrinsic Value_5Y_min---10.280----------
Market Cap28897170.800-15%33295612.000135520623.000-75%512394350.000-94%364946807.667-91%1193278926.600-97%954623141.280-97%
Net Profit Margin----0%-4.5840%-1.5280%-795510.4660%-636409.3530%
Operating Margin----0%-4.5420%-1.5140%-781400.2660%-625121.1770%
Operating Ratio----0%4.841-100%1.614-100%755298.698-100%604240.123-100%
Pb Ratio0.327-15%0.3770.974-61%2.808-87%1.797-79%3.112-88%2.490-85%
Pe Ratio-0.235+13%-0.271-0.968+258%-3.189+1078%-2.536+837%-15.624+5672%-12.499+4518%
Price Per Share0.541-15%0.6232.536-75%9.588-94%6.829-91%22.328-97%17.862-97%
Price To Free Cash Flow Ratio-0.292+13%-0.337-1.252+272%-3.514+944%-3.226+858%-23.288+6817%-18.631+5434%
Price To Total Gains Ratio-1.141+13%-1.315-18.888+1336%-1.429+9%-12.553+855%-34.806+2547%-34.806+2547%
Quick Ratio--9.3409.710-4%12.868-27%14.173-34%21.717-57%18.516-50%
Return On Assets---0.254-0.200-21%-0.181-29%-0.161-37%-0.120-53%-0.127-50%
Return On Equity---0.348-0.269-23%-0.154-56%-0.170-51%-0.123-65%-0.151-57%
Total Gains Per Share---0.474-0.355-25%-0.356-25%-0.398-16%-0.010-98%0.066-817%
Usd Book Value--88295000.000124509250.000-29%183837750.000-52%195043500.000-55%229924900.000-62%187893560.000-53%
Usd Book Value Change Per Share---0.474-0.355-25%-0.356-25%-0.398-16%-0.010-98%0.066-817%
Usd Book Value Per Share--1.6522.330-29%3.440-52%3.649-55%4.302-62%3.516-53%
Usd Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Usd Enterprise Value--98521612.000225499123.000-56%653284850.000-85%522563557.667-81%1464576606.947-93%1464576606.947-93%
Usd Eps---0.575-0.608+6%-0.777+35%-0.663+15%-0.540-6%-0.454-21%
Usd Free Cash Flow---24723000.000-27252500.000+10%-35301000.000+43%-29008916.667+17%-23587050.000-5%-19812640.000-20%
Usd Free Cash Flow Per Share---0.463-0.510+10%-0.661+43%-0.543+17%-0.441-5%-0.371-20%
Usd Free Cash Flow To Equity Per Share---0.461-0.380-18%-0.368-20%-0.387-16%-0.011-98%0.064-822%
Usd Market Cap28897170.800-15%33295612.000135520623.000-75%512394350.000-94%364946807.667-91%1193278926.600-97%954623141.280-97%
Usd Price Per Share0.541-15%0.6232.536-75%9.588-94%6.829-91%22.328-97%17.862-97%
Usd Profit---30754000.000-32505750.000+6%-41550500.000+35%-35238083.333+15%-28546250.000-7%-23824880.000-23%
Usd Revenue----0%620000.000-100%206666.667-100%150350.059-100%338320.047-100%
Usd Total Gains Per Share---0.474-0.355-25%-0.356-25%-0.398-16%-0.010-98%0.066-817%
 EOD+3 -5MRQTTM+10 -23YOY+11 -243Y+11 -245Y+5 -3210Y+5 -32

3.3 Fundamental Score

Let's check the fundamental score of Alx Oncology HoldingsĀ  based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.235
Price to Book Ratio (EOD)Between0-10.327
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.340
Current Ratio (MRQ)Greater than15.471
Debt to Asset Ratio (MRQ)Less than10.270
Debt to Equity Ratio (MRQ)Less than10.369
Return on Equity (MRQ)Greater than0.15-0.348
Return on Assets (MRQ)Greater than0.05-0.254
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Alx Oncology HoldingsĀ  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.364
Ma 20Greater thanMa 500.494
Ma 50Greater thanMa 1000.510
Ma 100Greater thanMa 2000.792
OpenGreater thanClose0.554
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Alx Oncology HoldingsĀ 

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-05-27 23:14:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitĀ Alx Oncology HoldingsĀ  earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Ā means thatĀ $0.00 for each $1Ā in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-458.4%+458.4%
TTM-5Y-79,551,046.6%+79,551,046.6%
5Y-79,551,046.6%10Y-63,640,935.3%-15,910,111.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--94.6%+94.6%
TTM--144.8%+144.8%
YOY-458.4%-198.4%-260.0%
3Y-152.8%-256.0%+103.2%
5Y-79,551,046.6%-348.5%-79,550,698.1%
10Y-63,640,935.3%-479.9%-63,640,455.4%
4.3.1.2. Return on Assets

Shows howĀ efficientĀ Alx Oncology HoldingsĀ  is using its assets to generate profit.

  • Above 5% is considered healthyĀ but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • -25.4% Return on Assets means thatĀ Alx Oncology HoldingsĀ  generatedĀ $-0.25 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alx Oncology HoldingsĀ :

  • The MRQ is -25.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.4%TTM-20.0%-5.4%
TTM-20.0%YOY-18.1%-1.9%
TTM-20.0%5Y-12.0%-8.0%
5Y-12.0%10Y-12.7%+0.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.4%-11.4%-14.0%
TTM-20.0%-11.4%-8.6%
YOY-18.1%-11.2%-6.9%
3Y-16.1%-11.7%-4.4%
5Y-12.0%-11.9%-0.1%
10Y-12.7%-13.8%+1.1%
4.3.1.3. Return on Equity

Shows how efficient Alx Oncology HoldingsĀ  is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • -34.8% Return on Equity means Alx Oncology HoldingsĀ  generated $-0.35Ā for eachĀ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alx Oncology HoldingsĀ :

  • The MRQ is -34.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -26.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-34.8%TTM-26.9%-7.9%
TTM-26.9%YOY-15.4%-11.5%
TTM-26.9%5Y-12.3%-14.6%
5Y-12.3%10Y-15.1%+2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-34.8%-13.3%-21.5%
TTM-26.9%-14.5%-12.4%
YOY-15.4%-14.3%-1.1%
3Y-17.0%-16.9%-0.1%
5Y-12.3%-17.2%+4.9%
10Y-15.1%-19.9%+4.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Alx Oncology HoldingsĀ .

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresĀ how efficient Alx Oncology HoldingsĀ  is operatingĀ .

  • Measures how much profit Alx Oncology HoldingsĀ  makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • An Operating Margin of 0.0%Ā means the company generated $0.00 Ā for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-454.2%+454.2%
TTM-5Y-78,140,026.6%+78,140,026.6%
5Y-78,140,026.6%10Y-62,512,117.7%-15,627,908.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM--252.1%+252.1%
YOY-454.2%-210.7%-243.5%
3Y-151.4%-220.1%+68.7%
5Y-78,140,026.6%-351.8%-78,139,674.8%
10Y-62,512,117.7%-449.6%-62,511,668.1%
4.3.2.2. Operating Ratio

Measures how efficient Alx Oncology HoldingsĀ  is keepingĀ operating costsĀ low.

  • Below 1 is considered healthy (always compare toĀ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY4.841-4.841
TTM-5Y755,298.698-755,298.698
5Y755,298.69810Y604,240.123+151,058.575
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.111-2.111
TTM-2.737-2.737
YOY4.8413.107+1.734
3Y1.6143.655-2.041
5Y755,298.6984.745+755,293.953
10Y604,240.1236.397+604,233.726
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Alx Oncology HoldingsĀ .

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Alx Oncology HoldingsĀ  is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toĀ Biotechnology industry mean).
  • A Current Ratio of 5.47Ā means the company has $5.47 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 5.471. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.485. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.471TTM5.485-0.015
TTM5.485YOY7.152-1.667
TTM5.4855Y17.561-12.075
5Y17.56110Y15.204+2.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4713.616+1.855
TTM5.4853.745+1.740
YOY7.1524.149+3.003
3Y7.9574.628+3.329
5Y17.5615.766+11.795
10Y15.2046.150+9.054
4.4.3.2. Quick Ratio

Measures if Alx Oncology HoldingsĀ  is able to pay off Short-term Debt but only usingĀ theĀ most liquid assets.

  • Above 1 is considered healthy butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Quick Ratio of 9.34Ā means the company can pay off $9.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 9.340. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.710. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.340TTM9.710-0.370
TTM9.710YOY12.868-3.158
TTM9.7105Y21.717-12.008
5Y21.71710Y18.516+3.202
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.3402.891+6.449
TTM9.7103.143+6.567
YOY12.8683.843+9.025
3Y14.1734.308+9.865
5Y21.7175.702+16.015
10Y18.5166.505+12.011
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Alx Oncology HoldingsĀ .

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Ā of Alx Oncology HoldingsĀ Ā assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareĀ Alx Oncology HoldingsĀ  to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27Ā means that Alx Oncology HoldingsĀ  assets areĀ financed with 27.0% credit (debt) and the remaining percentage (100% - 27.0%)Ā is financed by its owners/shareholders.Ā 

Let's take a look of the Debt to Asset Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.270. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.255. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.270TTM0.255+0.014
TTM0.255YOY0.204+0.052
TTM0.2555Y0.183+0.072
5Y0.18310Y0.191-0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2700.339-0.069
TTM0.2550.356-0.101
YOY0.2040.335-0.131
3Y0.1910.339-0.148
5Y0.1830.349-0.166
10Y0.1910.382-0.191
4.5.4.2. Debt to Equity Ratio

Measures ifĀ Alx Oncology HoldingsĀ  is able toĀ pay off its debts by usingĀ shareholders equity.

  • Below 2 is considered healthy butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A Debt to Equity ratio of 36.9% means that company has $0.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alx Oncology HoldingsĀ :

  • The MRQ is 0.369. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.344. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.369TTM0.344+0.026
TTM0.344YOY0.182+0.161
TTM0.3445Y0.191+0.152
5Y0.19110Y0.157+0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3690.387-0.018
TTM0.3440.438-0.094
YOY0.1820.414-0.232
3Y0.2050.455-0.250
5Y0.1910.464-0.273
10Y0.1570.504-0.347
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresĀ how much money you payĀ for each share forĀ every $1 in earnings Alx Oncology HoldingsĀ  generates.

  • Above 15 is considered overpriced butĀ always compareĀ Alx Oncology HoldingsĀ  to theĀ Biotechnology industry mean.
  • A PE ratio of -0.27 means the investor is paying $-0.27Ā for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is -0.235. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.271. Based on the earnings, the company is expensive. -2
  • The TTM is -0.968. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.235MRQ-0.271+0.036
MRQ-0.271TTM-0.968+0.697
TTM-0.968YOY-3.189+2.221
TTM-0.9685Y-15.624+14.655
5Y-15.62410Y-12.499-3.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.235-2.145+1.910
MRQ-0.271-2.030+1.759
TTM-0.968-2.526+1.558
YOY-3.189-3.682+0.493
3Y-2.536-3.711+1.175
5Y-15.624-6.083-9.541
10Y-12.499-6.715-5.784
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is -0.292. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.337. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.252. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.292MRQ-0.337+0.044
MRQ-0.337TTM-1.252+0.915
TTM-1.252YOY-3.514+2.262
TTM-1.2525Y-23.288+22.037
5Y-23.28810Y-18.631-4.658
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.292-2.986+2.694
MRQ-0.337-2.697+2.360
TTM-1.252-3.653+2.401
YOY-3.514-4.430+0.916
3Y-3.226-5.157+1.931
5Y-23.288-8.483-14.805
10Y-18.631-9.320-9.311
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofĀ Alx Oncology HoldingsĀ  is to cheap or to expensiveĀ compared to its book value.

  • At or below 1 is considered healthyĀ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.38 means the investor is paying $0.38Ā for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alx Oncology HoldingsĀ :

  • The EOD is 0.327. Based on the equity, the company is cheap. +2
  • The MRQ is 0.377. Based on the equity, the company is cheap. +2
  • The TTM is 0.974. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.327MRQ0.377-0.050
MRQ0.377TTM0.974-0.597
TTM0.974YOY2.808-1.834
TTM0.9745Y3.112-2.138
5Y3.11210Y2.490+0.622
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.3272.023-1.696
MRQ0.3771.855-1.478
TTM0.9742.173-1.199
YOY2.8082.479+0.329
3Y1.7972.589-0.792
5Y3.1123.728-0.616
10Y2.4904.370-1.880
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alx Oncology HoldingsĀ .

4.8.1. Institutions holding Alx Oncology HoldingsĀ 

Institutions are holding 79.617% of the shares of Alx Oncology HoldingsĀ .

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31venBio Partners LLC18.16614.891969992500
2024-12-31Redmile Group, LLC6.90990.42943689611-146965-3.8306
2025-03-31TANG CAPITAL MANAGEMENT LLC5.91480.10893158265-138618-4.2045
2025-03-31BlackRock Inc4.333302313800-70447-2.9547
2024-12-31Millennium Management LLC3.98740.001721291101267366.3293
2025-03-31Vanguard Group Inc3.442101837923-49079-2.6009
2025-03-31Bank of America Corp2.71890.0001145177841645240.2242
2024-12-31Almitas Capital LLC2.29030.4475122294512229450
2024-12-31Bank of Montreal1.5480.00068265828265820
2025-03-31Geode Capital Management, LLC1.44380770907308014.1617
2025-03-31State Street Corp1.34630718853347305.0766
2025-03-31BMO Capital Markets Corp.1.2780.0002682394-144188-17.4439
2025-03-31Two Sigma Advisers, LLC1.27540.001681000-142900-17.3443
2025-03-31MPM Oncology Impact Management LP1.030.0589550000-841434-60.4724
2025-03-31Two Sigma Investments LLC1.01630.0007542655-161476-22.9327
2025-03-31Privium Fund Management B.V.0.95340.082750905900
2025-03-31Los Angeles Capital Management LLC0.76770.001140993810851936.0027
2024-12-31UBS Group AG0.76420.00014080563788161295.5404
2025-03-31Goldman Sachs Group Inc0.6990373214-195795-34.4098
2025-03-31Morgan Stanley - Brokerage Accounts0.67130358460-2140642-85.6564
Total 60.55626.023932334475-885963-2.7%

4.9.2. Funds holding Alx Oncology HoldingsĀ 

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31HBM Healthcare Investments AG Ord8.42760.13994500000107307131.3129
2025-04-30Vanguard Total Stock Mkt Idx Inv1.8439098458600
2025-04-30iShares Russell 2000 ETF1.54440.00088246651390.0169
2025-04-30Vanguard Institutional Extnd Mkt Idx Tr0.75680.000240409600
2025-02-28Fidelity Small Cap Index0.6530.001534867700
2025-04-30iShares Russell 2000 Growth ETF0.55630.001529703800
2025-04-30State St Russell Sm/Mid CpĀ® Indx SL Cl I0.46940.000425061600
2025-04-30Vanguard Russell 2000 ETF0.30810.000816449795416.1572
2025-03-31Fidelity Extended Market Index0.30610.000316346649553.126
2025-04-30Schwab US Small-Cap ETFā„¢0.25170.0004134423-63-0.0468
2025-04-30SEI Small Cap A (SIIT)0.23140.02751235603584040.8573
2025-03-31Vanguard VIF Small Co Gr0.23010.005712283700
2025-04-30SEI Small Cap II A (SIIT)0.19650.02321049403155042.9895
2025-04-30State St Russell Sm CapĀ® Indx SL Cl I0.19370.000710343700
2025-04-30Xtrackers Russell 2000 ETF 1C0.18780.003610027600
2025-04-30SPDRĀ® Russell 2000 US Small Cap ETF0.15530.001382928-8086-8.8843
2025-03-31NT R2000 Index Fund - NL0.15140.0009808631060.1313
2025-04-30Vanguard Health Care ETF0.14810.000279093-702-0.8798
2025-04-30Schwab Small Cap Index0.14620.00077809000
2025-04-30iShares Micro-Cap ETF0.14180.00547572900
Total 16.89960.2159023817+1146351+12.7%

5.3. Insider Transactions

Insiders are holding 2.453% of the shares of Alx Oncology HoldingsĀ .

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-06Shelly PintoSELL22211.8
2024-12-30Jaume PonsSELL107961.58
2024-12-30Shelly PintoSELL14261.58
2024-12-02Rekha HemrajaniBUY300001.55
2024-08-14Shelly PintoSELL5642.58
2024-08-14Sophia RandolphSELL13652.58
2024-07-11Jaume PonsSELL200007.9
2024-07-05Shelly PintoSELL18235.5
2024-07-01Shelly PintoSELL13735.82
2024-07-01Sophia RandolphSELL32735.82
2024-06-13Peter S GarciaBUY120008.53
2024-06-04Jaume PonsSELL200008.43
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets120,900
Total Liabilities32,605
Total Stockholder Equity88,295
 As reported
Total Liabilities 32,605
Total Stockholder Equity+ 88,295
Total Assets = 120,900

Assets

Total Assets120,900
Total Current Assets102,532
Long-term Assets18,368
Total Current Assets
Cash And Cash Equivalents 20,614
Short-term Investments 77,217
Other Current Assets 4,701
Total Current Assets  (as reported)102,532
Total Current Assets  (calculated)102,532
+/-0
Long-term Assets
Property Plant Equipment 2,703
Long Term Investments 9,161
Long-term Assets Other 6,504
Long-term Assets  (as reported)18,368
Long-term Assets  (calculated)18,368
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,742
Long-term Liabilities13,863
Total Stockholder Equity88,295
Total Current Liabilities
Short-term Debt 1,739
Short Long Term Debt 1,739
Accounts payable 3,937
Other Current Liabilities 9,129
Total Current Liabilities  (as reported)18,742
Total Current Liabilities  (calculated)16,544
+/- 2,198
Long-term Liabilities
Long term Debt 8,232
Long-term Liabilities Other 5,631
Long-term Liabilities  (as reported)13,863
Long-term Liabilities  (calculated)13,863
+/-0
Total Stockholder Equity
Common Stock53
Retained Earnings -651,876
Accumulated Other Comprehensive Income 118
Other Stockholders Equity 740,000
Total Stockholder Equity (as reported)88,295
Total Stockholder Equity (calculated)88,295
+/-0
Other
Capital Stock53
Cash and Short Term Investments 97,831
Common Stock Shares Outstanding 53,359
Liabilities and Stockholders Equity 120,900
Net Debt -18,875
Net Invested Capital 98,266
Net Working Capital 83,790
Property Plant and Equipment Gross 11,240
Short Long Term Debt Total 1,739



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
10,676
108,399
103,112
262,449
436,054
432,910
421,289
399,728
380,183
363,676
346,018
317,689
306,489
278,138
245,932
220,107
242,553
212,650
214,618
185,715
147,775
120,900
120,900147,775185,715214,618212,650242,553220,107245,932278,138306,489317,689346,018363,676380,183399,728421,289432,910436,054262,449103,112108,39910,676000
   > Total Current Assets 
8,262
0
0
9,809
107,413
100,664
262,404
434,219
432,327
412,277
388,963
367,019
321,525
316,847
290,808
270,969
232,536
219,561
199,071
188,659
167,864
168,712
155,895
134,352
102,532
102,532134,352155,895168,712167,864188,659199,071219,561232,536270,969290,808316,847321,525367,019388,963412,277432,327434,219262,404100,664107,4139,809008,262
       Cash And Cash Equivalents 
-8,262
0
0
9,017
105,035
98,103
259,484
434,219
429,855
409,964
385,149
363,667
159,086
66,378
49,054
282,906
63,194
38,039
19,584
22,406
14,041
15,534
16,102
17,567
20,614
20,61417,56716,10215,53414,04122,40619,58438,03963,194282,90649,05466,378159,086363,667385,149409,964429,855434,219259,48498,103105,0359,01700-8,262
       Short-term Investments 
16,524
0
0
0
0
0
0
0
0
0
0
0
157,510
246,988
235,855
217,385
164,750
174,797
170,425
160,330
143,396
141,189
132,472
110,190
77,217
77,217110,190132,472141,189143,396160,330170,425174,797164,750217,385235,855246,988157,5100000000000016,524
       Net Receivables 
0
0
0
536
1,191
527
527
0
0
0
0
0
600
900
700
1,000
800
500
600
1,000
1,100
6,240
1,183
0
0
001,1836,2401,1001,0006005008001,000700900600000005275271,191536000
       Other Current Assets 
0
0
0
256
1,187
2,034
2,393
3,546
4,944
4,626
7,628
6,704
9,858
6,962
11,798
4,762
4,592
6,725
9,062
5,923
10,427
5,749
6,113
6,595
4,701
4,7016,5956,1135,74910,4275,9239,0626,7254,5924,76211,7986,9629,8586,7047,6284,6264,9443,5462,3932,0341,187256000
   > Long-term Assets 
-8,262
0
0
867
986
2,448
45
1,835
583
9,012
10,765
13,164
42,151
29,171
26,881
35,520
45,602
26,371
21,036
53,894
44,786
45,906
29,820
13,423
18,368
18,36813,42329,82045,90644,78653,89421,03626,37145,60235,52026,88129,17142,15113,16410,7659,0125831,835452,44898686700-8,262
       Property Plant Equipment 
0
0
0
860
757
37
45
52
47
167
562
3,472
6,967
8,235
8,639
9,813
9,551
9,066
9,808
10,841
10,245
10,704
10,312
9,632
2,703
2,7039,63210,31210,70410,24510,8419,8089,0669,5519,8138,6398,2356,9673,47256216747524537757860000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
25,109
10,860
8,217
16,699
28,220
11,647
6,435
35,411
27,049
29,475
14,036
3,524
9,161
9,1613,52414,03629,47527,04935,4116,43511,64728,22016,6998,21710,86025,109000000000000
       Long-term Assets Other 
-8,262
0
0
7
229
2,411
0
1,783
536
8,845
10,203
9,692
10,075
10,076
10,025
9,008
7,831
5,658
4,793
7,576
7,426
5,661
5,472
267
6,504
6,5042675,4725,6617,4267,5764,7935,6587,8319,00810,02510,07610,0759,69210,2038,8455361,78302,411229700-8,262
> Total Liabilities 
0
0
0
10,952
9,282
12,467
10,433
436,054
14,426
16,275
14,556
17,134
20,080
29,699
30,726
43,025
37,750
33,240
51,355
52,841
48,455
55,301
48,908
34,157
32,605
32,60534,15748,90855,30148,45552,84151,35533,24037,75043,02530,72629,69920,08017,13414,55616,27514,426436,05410,43312,4679,28210,952000
   > Total Current Liabilities 
0
0
0
4,984
3,990
7,719
7,197
6,204
14,129
13,979
12,488
15,295
15,308
23,952
25,243
28,325
21,891
17,572
35,142
36,001
32,228
38,449
32,340
18,500
18,742
18,74218,50032,34038,44932,22836,00135,14217,57221,89128,32525,24323,95215,30815,29512,48813,97914,1296,2047,1977,7193,9904,984000
       Short-term Debt 
0
0
0
0
857
1,714
2,571
2,571
235
539
703
742
1,025
1,075
1,117
1,041
956
800
823
1,575
1,786
1,743
0
435
1,739
1,73943501,7431,7861,5758238009561,0411,1171,0751,0257427035392352,5712,5711,7148570000
       Short Long Term Debt 
0
0
0
0
857
1,714
2,571
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
435
1,739
1,73943500000000000000002,5711,7148570000
       Accounts payable 
0
0
0
3,748
1,987
1,865
1,421
4
7,350
5,806
3,683
3,764
5,133
8,680
5,880
8,073
9,826
4,115
13,001
8,591
6,227
8,146
7,891
4,497
3,937
3,9374,4977,8918,1466,2278,59113,0014,1159,8268,0735,8808,6805,1333,7643,6835,8067,35041,4211,8651,9873,748000
       Other Current Liabilities 
0
0
0
1,236
1,146
4,140
3,205
6,021
6,365
7,634
8,102
10,789
9,150
14,197
18,246
19,211
11,109
13,457
22,141
25,835
24,215
28,560
24,449
13,568
9,129
9,12913,56824,44928,56024,21525,83522,14113,45711,10919,21118,24614,1979,15010,7898,1027,6346,3656,0213,2054,1401,1461,236000
   > Long-term Liabilities 
0
0
0
5,968
5,292
4,748
3,236
5
297
2,296
2,068
1,839
4,772
5,747
5,483
14,700
15,859
15,668
16,213
16,840
16,227
16,852
16,568
15,657
13,863
13,86315,65716,56816,85216,22716,84016,21315,66815,85914,7005,4835,7474,7721,8392,0682,29629753,2364,7485,2925,968000
       Long term Debt Total 
0
0
0
0
4,672
0
0
0
0
0
0
0
0
0
0
9,389
9,450
0
0
0
0
0
0
0
0
000000009,4509,38900000000004,6720000
       Other Liabilities 
0
0
0
0
620
820
47
5
0
0
0
1,839
1
5,747
0
53
0
1,309
0
0
0
0
0
0
0
00000001,30905305,74711,8390005478206200000
       Deferred Long Term Liability 
0
0
0
0
200
2,411
0
0
0
0
0
9,548
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000009,548000002,4112000000
> Total Stockholder Equity
9,155
0
0
-276
99,117
90,645
252,016
429,845
418,484
405,014
385,172
-201,985
343,596
316,319
286,963
-325,467
240,388
212,692
-440,800
189,712
164,195
159,317
136,807
113,618
88,295
88,295113,618136,807159,317164,195189,712-440,800212,692240,388-325,467286,963316,319343,596-201,985385,172405,014418,484429,845252,01690,64599,117-276009,155
   Common Stock
0
0
0
3
3
3
37
40
40
40
40
41
41
41
41
41
41
41
41
50
50
52
53
53
53
53535352505041414141414141414040404037333000
   Retained Earnings -651,876-621,122-591,959-561,252-521,853-486,272-440,800-389,810-355,651-325,467-294,758-259,438-226,518-201,985-173,547-148,981-132,707-118,522-99,748-89,567-78,236-72,782000
   Capital Surplus 
0
0
0
0
2,289
0
0
548,327
551,151
553,955
558,679
564,993
570,679
576,972
583,184
589,735
596,086
0
0
0
0
0
0
0
0
00000000596,086589,735583,184576,972570,679564,993558,679553,955551,151548,327002,2890000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
3,589
3,870
5,166
351,727
548,327
551,151
553,955
558,679
564,993
570,679
576,972
583,184
589,735
596,086
602,773
609,737
675,678
685,970
720,590
728,150
734,412
740,000
740,000734,412728,150720,590685,970675,678609,737602,773596,086589,735583,184576,972570,679564,993558,679553,955551,151548,327351,7275,1663,8703,589000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-142,467
Operating Income-142,467-142,467
 
Operating Expense (+$)
Research Development116,373
Selling General Administrative26,094
Selling And Marketing Expenses0
Operating Expense142,467142,467
 
Net Interest Income (+$)
Interest Income9,366
Interest Expense-1,729
Other Finance Cost-0
Net Interest Income7,637
 
Pretax Income (+$)
Operating Income-142,467
Net Interest Income7,637
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-134,850-150,084
EBIT - interestExpense = -134,850
-134,850
-133,121
Interest Expense1,729
Earnings Before Interest and Taxes (EBIT)-133,121-133,121
Earnings Before Interest and Taxes (EBITDA)-132,249
 
After tax Income (+$)
Income Before Tax-134,850
Tax Provision-0
Net Income From Continuing Ops-134,850-134,850
Net Income-134,850
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses142,467
Total Other Income/Expenses Net7,617-7,637
 

Technical Analysis of Alx Oncology HoldingsĀ 
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alx Oncology HoldingsĀ . The general trend of Alx Oncology HoldingsĀ  is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alx Oncology HoldingsĀ 's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Alx Oncology HoldingsĀ  Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportĀ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceĀ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alx Oncology HoldingsĀ .

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.66 < 0.9626 < 1.19.

The bearish price targets are: 0.4051.

Know someone who trades $ALXO? Share this with them.šŸ‘‡

Alx Oncology HoldingsĀ  Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theĀ moving averageĀ of the selected period.

  • Moving averages are laggingĀ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alx Oncology HoldingsĀ . The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alx Oncology HoldingsĀ  Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theĀ momentumĀ of theĀ selected period based on two moving averages.

  • MACD is aĀ lagging momentumĀ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alx Oncology HoldingsĀ . The current macd is 0.01022839.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alx Oncology HoldingsĀ  price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Alx Oncology HoldingsĀ . This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Alx Oncology HoldingsĀ  price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alx Oncology HoldingsĀ  Daily Moving Average Convergence/Divergence (MACD) ChartAlx Oncology HoldingsĀ  Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alx Oncology HoldingsĀ . The current adx is 21.61.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Alx Oncology HoldingsĀ  shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Alx Oncology HoldingsĀ  Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsĀ the current trend.
  • ShowsĀ potential entry signals.
  • ShowsĀ Ā potential exit signals.
  • Can be used to placeĀ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alx Oncology HoldingsĀ . The current sar is 0.52341581.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Alx Oncology HoldingsĀ  Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumĀ indicator, meaning the signals are instant.
  • RangesĀ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alx Oncology HoldingsĀ . The current rsi is 53.36. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Alx Oncology HoldingsĀ  Daily Relative Strength Index (RSI) ChartAlx Oncology HoldingsĀ  Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesĀ a certain price to multiple prices ranging over time.

  • LeadingĀ momentumĀ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesĀ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alx Oncology HoldingsĀ . The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alx Oncology HoldingsĀ  price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Alx Oncology HoldingsĀ  Daily Stochastic Oscillator ChartAlx Oncology HoldingsĀ  Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Ā the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alx Oncology HoldingsĀ . The current cci is 67.60.

Alx Oncology HoldingsĀ  Daily Commodity Channel Index (CCI) ChartAlx Oncology HoldingsĀ  Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alx Oncology HoldingsĀ . The current cmo is 11.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Alx Oncology HoldingsĀ  Daily Chande Momentum Oscillator (CMO) ChartAlx Oncology HoldingsĀ  Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Ā Shows the current price relative to the highest high over the last 14 days.
Ā 

  • Lagging momentum indicator
  • Ranging between 0 andĀ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alx Oncology HoldingsĀ . The current willr is -44.89693313.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Alx Oncology HoldingsĀ  is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Alx Oncology HoldingsĀ  Daily Williams %R ChartAlx Oncology HoldingsĀ  Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldĀ 

Score

Let's take a look at the Bollinger Bands of Alx Oncology HoldingsĀ .

Alx Oncology HoldingsĀ  Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alx Oncology HoldingsĀ . The current atr is 0.05023465.

Alx Oncology HoldingsĀ  Daily Average True Range (ATR) ChartAlx Oncology HoldingsĀ  Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Ā Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alx Oncology HoldingsĀ . The current obv is 2,449,069.

Alx Oncology HoldingsĀ  Daily On-Balance Volume (OBV) ChartAlx Oncology HoldingsĀ  Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alx Oncology HoldingsĀ . The current mfi is 67.90.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Alx Oncology HoldingsĀ  Daily Money Flow Index (MFI) ChartAlx Oncology HoldingsĀ  Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alx Oncology HoldingsĀ .

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-14MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-09BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Alx Oncology HoldingsĀ  Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alx Oncology HoldingsĀ  based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.364
Ma 20Greater thanMa 500.494
Ma 50Greater thanMa 1000.510
Ma 100Greater thanMa 2000.792
OpenGreater thanClose0.554
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Alx Oncology HoldingsĀ  with someone you think should read this too:
  • Are you bullish or bearish on Alx Oncology HoldingsĀ ? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alx Oncology HoldingsĀ ? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alx Oncology HoldingsĀ 

I send you an email if I find something interesting about Alx Oncology HoldingsĀ .


Comments

How you think about this?

Leave a comment

Stay informed about Alx Oncology HoldingsĀ .

Receive notifications about Alx Oncology HoldingsĀ  in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.